JP7337058B2 - ジアリールピリジン誘導体の製造方法 - Google Patents

ジアリールピリジン誘導体の製造方法 Download PDF

Info

Publication number
JP7337058B2
JP7337058B2 JP2020529019A JP2020529019A JP7337058B2 JP 7337058 B2 JP7337058 B2 JP 7337058B2 JP 2020529019 A JP2020529019 A JP 2020529019A JP 2020529019 A JP2020529019 A JP 2020529019A JP 7337058 B2 JP7337058 B2 JP 7337058B2
Authority
JP
Japan
Prior art keywords
added
formula
compound represented
salt
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020529019A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020009132A1 (ja
JPWO2020009132A5 (cg-RX-API-DMAC7.html
Inventor
祐一 安藝
史彦 鳥山
なつ樹 桜井
藍 亀田
友和 小倉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JPWO2020009132A1 publication Critical patent/JPWO2020009132A1/ja
Publication of JPWO2020009132A5 publication Critical patent/JPWO2020009132A5/ja
Priority to JP2023134392A priority Critical patent/JP2023159297A/ja
Application granted granted Critical
Publication of JP7337058B2 publication Critical patent/JP7337058B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020529019A 2018-07-04 2019-07-03 ジアリールピリジン誘導体の製造方法 Active JP7337058B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023134392A JP2023159297A (ja) 2018-07-04 2023-08-22 ジアリールピリジン誘導体の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018127197 2018-07-04
JP2018127197 2018-07-04
PCT/JP2019/026395 WO2020009132A1 (ja) 2018-07-04 2019-07-03 ジアリールピリジン誘導体の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023134392A Division JP2023159297A (ja) 2018-07-04 2023-08-22 ジアリールピリジン誘導体の製造方法

Publications (3)

Publication Number Publication Date
JPWO2020009132A1 JPWO2020009132A1 (ja) 2021-07-08
JPWO2020009132A5 JPWO2020009132A5 (cg-RX-API-DMAC7.html) 2022-07-01
JP7337058B2 true JP7337058B2 (ja) 2023-09-01

Family

ID=69059540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020529019A Active JP7337058B2 (ja) 2018-07-04 2019-07-03 ジアリールピリジン誘導体の製造方法
JP2023134392A Pending JP2023159297A (ja) 2018-07-04 2023-08-22 ジアリールピリジン誘導体の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023134392A Pending JP2023159297A (ja) 2018-07-04 2023-08-22 ジアリールピリジン誘導体の製造方法

Country Status (10)

Country Link
US (1) US11999724B2 (cg-RX-API-DMAC7.html)
EP (1) EP3819296B1 (cg-RX-API-DMAC7.html)
JP (2) JP7337058B2 (cg-RX-API-DMAC7.html)
CN (1) CN112368271A (cg-RX-API-DMAC7.html)
AU (1) AU2019299152A1 (cg-RX-API-DMAC7.html)
CA (1) CA3105328A1 (cg-RX-API-DMAC7.html)
ES (1) ES2925365T3 (cg-RX-API-DMAC7.html)
IL (1) IL279070B2 (cg-RX-API-DMAC7.html)
TW (1) TWI840378B (cg-RX-API-DMAC7.html)
WO (1) WO2020009132A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023090337A1 (cg-RX-API-DMAC7.html) 2021-11-19 2023-05-25

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016006706A1 (ja) 2014-07-07 2016-01-14 第一三共株式会社 テトラヒドロピラ二ルメチル基を有するピリドン誘導体
WO2018174219A1 (ja) 2017-03-24 2018-09-27 第一三共株式会社 Ａｘｌ阻害剤とＥＧＦＲチロシンキナーゼ阻害薬との併用治療法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404505PA (en) * 2012-01-31 2014-10-30 Daiichi Sankyo Co Ltd Pyridone derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016006706A1 (ja) 2014-07-07 2016-01-14 第一三共株式会社 テトラヒドロピラ二ルメチル基を有するピリドン誘導体
WO2018174219A1 (ja) 2017-03-24 2018-09-27 第一三共株式会社 Ａｘｌ阻害剤とＥＧＦＲチロシンキナーゼ阻害薬との併用治療法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHURCH, R. et al.，New Synthetic Routes to 3-, 5-, and 6-Aryl-2-chloropyridines，Journal of Organic Chemistry，1995年，Vol.60, No.12，pp.3750-3758，DOI: 10.1021/jo00117a029
EGE, G. et al.，A new synthesis of 4-(dimethylamino)-1,3-butadiene-1,1-dicarbonitriles and their cyclization to 2-am，Synthesis，1979年，No.5，pp.376-378，DOI: 10.1055/s-1080-28688
JUHASZ, L. et al.，Synthesis and glycogen phosphorylase inhibitor activity of 2,3-dihydrobenzo[1,4]dioxin derivatives，Bioorganic & Medicinal Chemistry，2007年，Vol.15, No.12，pp.4048-4056，DOI: 10.1016/j.bmc.2007.03.084
VILLEMIN, D. et al.，Solventless convenient synthesis of new cyano-2-aminopyridine derivatives from enamino nitriles，Tetrahedron Letters，2013年，Vol.54, No.13，pp.1664-1668，DOI: 10.1016/j.tetlet.2013.01.021

Also Published As

Publication number Publication date
TW202005962A (zh) 2020-02-01
US20210188823A1 (en) 2021-06-24
JP2023159297A (ja) 2023-10-31
ES2925365T3 (es) 2022-10-17
CA3105328A1 (en) 2020-01-09
IL279070B2 (en) 2024-05-01
JPWO2020009132A1 (ja) 2021-07-08
CN112368271A (zh) 2021-02-12
WO2020009132A1 (ja) 2020-01-09
EP3819296B1 (en) 2022-06-29
AU2019299152A1 (en) 2021-03-04
US11999724B2 (en) 2024-06-04
AU2019299152A2 (en) 2021-03-11
IL279070A (en) 2021-01-31
TWI840378B (zh) 2024-05-01
IL279070B1 (en) 2024-01-01
EP3819296A4 (en) 2021-06-09
EP3819296A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
CN110678178B (zh) Mk2抑制剂的形式和组合物
AU2015414743B2 (en) Process for the preparation of kinase inhibitors and intermediates thereof
JP2025138809A (ja) ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶性塩形態
JP6873053B2 (ja) タンパク質脱アセチル化阻害剤の製造方法
JP5047160B2 (ja) ４−［［５−［（シクロプロピルアミノ）カルボニル］−２−メチルフェニル］アミノ］−５−メチル−Ｎ−プロピルピロロ［２，１−ｆ］［１，２，４］トリアジン−６−カルボキサミドの塩の製造法、および該製造法において製造される新規の安定なフォーム
JP7704681B2 (ja) センタナファジンの製造方法
JP2021511299A (ja) 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
JP2023159297A (ja) ジアリールピリジン誘導体の製造方法
WO2016127963A1 (en) Solid forms of palbociclib salts
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
KR20180033514A (ko) Fgfr 억제제를 제조하기 위한 방법
JP2020530497A (ja) ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態
JP7776258B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
JP6165335B2 (ja) ゲフィチニブの新規な結晶形およびその製造方法
JP2014515381A (ja) エピルビシン塩酸塩の結晶化
JP6770962B2 (ja) チアゾール誘導体の製造方法
JP7492997B2 (ja) オラパリブの製造方法
TW202602874A (zh) Akt1抑制劑及其鹽之固態形式
KR20240089380A (ko) 마보릭사포의 합성 및 그 중간체
HK40047091A (en) Method for producing diarylpyridine derivatives
JPH01242585A (ja) ベンゾフロ〔３，２−ｃ〕キノリン誘導体の製造方法
KR20150084155A (ko) Ｎ-((1-(3-(1,2,3-트리아졸-1-일)프로필)피페리딘-4-일)메틸)-4-아미노-5-클로로-2-메톡시벤즈아미드 유도체의 결정형 및 이의 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230822

R150 Certificate of patent or registration of utility model

Ref document number: 7337058

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150